Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation

NCT02666157 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

3672

Enrollment

OTHER

Sponsor class

Conditions

Atrial Fibrillation

Interventions

DRUG: Dabigatran etexilate
DRUG: Rivaroxaban
DRUG: Apixaban

Sponsor

National Cheng-Kung University Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]